神经母细胞瘤动物模型研究进展与应用

doi:10.12300/j.issn.1674-5817.2022.194

实验动物与比较医学 ›› 2023, Vol. 43 ›› Issue (3): 288-296.DOI: 10.12300/j.issn.1674-5817.2022.194

神经母细胞瘤动物模型研究进展与应用

谭志刚¹^,²(), 刘锦信¹^,², 郑楚雅¹^,², 廖文峰¹^,², 冯露平¹^,², 彭红丽¹^,², 严秀³, 卓振建¹^,²()()

^1.北京大学深圳研究生院实验动物中心, 深圳 518055
^2.省部共建肿瘤化学基因组学国家重点实验室, 深圳 518055
^3.佛山科学技术学院, 佛山 528200

收稿日期:2022-12-29 修回日期:2023-04-11 出版日期:2023-06-25 发布日期:2023-06-25
通讯作者: 卓振建（1990—），男，博士，副研究员，主要从事肿瘤模型构建、实验动物管理、肿瘤机制研究。E-mail： zhenjianzhuo@163.com。ORCID： 0000-0003-0142-4086
作者简介:谭志刚（1989—），男，硕士，兽医师，主要从事实验动物设施管理、实验动物疾病研究等。E-mail： 18819267200@163.com
基金资助:
国家自然科学基金项目“遗传变异调控ALKBH5基因表达影响神经母细胞瘤迁移侵袭的作用及机制研究”(82002636);深圳市自然科学基金项目“N1－甲基腺苷修饰基因与神经母细胞瘤遗传易感的机制研究”(JCYJ20220531093213030)

Advances and Applications in Animal Models of Neuroblastoma

Zhigang TAN¹^,²(), Jinxin LIU¹^,², Chuya ZHENG¹^,², Wenfeng LIAO¹^,², Luping FENG¹^,², Hongli PENG¹^,², Xiu YAN³, Zhenjian ZHUO¹^,²()()

^1.Laboratory Animal Center, Peking University Shenzhen Graduate School, Shenzhen 518055, China
^2.State Key Laboratory of Chemical Oncogenomics, Shenzhen 518055, China
^3.Foshan University, Foshan 528200, China

Received:2022-12-29 Revised:2023-04-11 Published:2023-06-25 Online:2023-06-25
Correspondence to: ZHUO Zhenjian (ORCID: 0000-0003-0142-4086), E-mail: zhenjianzhuo@163.com

摘要/Abstract

摘要：

神经母细胞瘤（neuroblastoma，NB）是儿童最常见的实体恶性肿瘤，居我国儿童肿瘤发病率第四位，占儿童肿瘤死亡人数的15%，高危患者存活率低。目前对于NB的发病及药物治疗机制知之甚少。NB动物模型可以表征NB发展特征，是研究预防和治疗NB的重要工具，然而尚未有一种动物模型可以模拟人类NB的所有特征。本文介绍了当前研究较多的几种NB动物模型（小鼠模型、鸡胚绒毛尿囊膜模型和斑马鱼模型），并对每种NB动物模型的种类、构建方法、特征、优缺点及研究进展做了详细阐述，同时对NB的应用方向及前景进行概括，以期为NB动物模型构建和NB治疗等提供理论依据。

关键词: 神经母细胞瘤, 动物模型, 小鼠, 鸡胚绒毛尿囊膜, 斑马鱼

Abstract:

Neuroblastoma (NB) is one of the most common malignant solid tumors in children, ranks fourth in the incidence of pediatric tumors, and accounts for 15% of pediatric tumor deaths in children in China. Despite the development of new treatment options, the prognosis for high-risk patients is still poor. An animal model that can replicate the tumorigenesis of NB is an important tool for the prevention and treatment of NB. However, there are currently no animal models that can simulate all features of human NB. To provide a reference for the construction of animal models and treatment of NB, this article introduced several animal models of NB that have been extensively researched: the mouse, chick embryo chorioallantoic membrane, and zebrafish models. At the same time, it elaborated on the species, construction methods, characteristics, advantages and disadvantages, and research progress in NB.

Key words: Neuroblastoma, Animal model, Mice, Chick embryo chorioallantoic-membrane, Zebrafish

中图分类号:

R-332

谭志刚,刘锦信,郑楚雅,等. 神经母细胞瘤动物模型研究进展与应用[J]. 实验动物与比较医学, 2023, 43(3): 288-296. DOI: 10.12300/j.issn.1674-5817.2022.194.

Zhigang TAN,Jinxin LIU,Chuya ZHENG,et al. Advances and Applications in Animal Models of Neuroblastoma[J]. Laboratory Animal and Comparative Medicine, 2023, 43(3): 288-296. DOI: 10.12300/j.issn.1674-5817.2022.194.

图/表 3

参考文献 81

1	ZAFAR A, WANG W, LIU G, et al. Molecular targeting therapies for neuroblastoma: progress and challenges[J]. Med Res Rev, 2021, 41(2):961-1021. DOI: 10.1002/med.21750 .
2	CHUNG C, BOTERBERG T, LUCAS J, et al. Neuroblastoma[J]. Pediatr Blood Cancer, 2021, 68:e28473. DOI: 10.1002/pbc. 28473 .
3	SUN X F, ZHEN Z J, GUO Y, et al. Oral metronomic maintenance therapy can improve survival in high-risk neuroblastoma patients not treated with ASCT or anti-GD2 antibodies[J]. Cancers, 2021, 13(14):3494. DOI: 10.3390/cancers13143494 .
4	HELSON L, DAS S K, HAJDU S I. Human neuroblastoma in nude mice[J]. Cancer Res, 1975, 35(9): 2594-2599.
5	BOGDEN A E, COBB W R, LEPAGE D J, et al. Chemotherapy responsiveness of human tumors as first transplant generation xenografts in the normal mouse: six-day subrenal capsule assay[J]. Cancer, 1981, 48(1):10-20. DOI: 10.1002/1097-0142(19810701)48:1<10: AID-CNCR2820480105>3.0.CO;2-I .
6	KHANNA C, JABOIN J J, DRAKOS E, et al. Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis[J]. In Vivo, 2002, 16(2):77-85.
7	ROWE D H, HUANG J Z, LI J, et al. Suppression of primary tumor growth in a mouse model of human neuroblastoma[J]. J Pediatr Surg, 2000, 35(6):977-981. DOI: 10.1053/jpsu. 2000.6946 .
8	FLICKINGER K S, JUDWARE R, LECHNER R, et al. Integrin expression in human neuroblastoma cells with or without N-myc amplification and in ectopic/orthotopic nude mouse tumors[J]. Exp Cell Res, 1994, 213(1):156-163. DOI: 10.1006/excr.1994.1185 .
9	KANG J, ISHOLA T A, BAREGAMIAN N, et al. Bombesin induces angiogenesis and neuroblastoma growth[J]. Cancer Lett, 2007, 253(2):273-281. DOI: 10.1016/j.canlet.2007.02.007 .
10	刘波, 苗佳宁, 张斯萌, 等. 神经母细胞瘤肾上腺原位移植瘤动物模型的建立[J]. 中国比较医学杂志, 2021, 31(12):1-6. DOI: 10.3969/j.issn.1671-7856.2021.12.001 .
	LIU B, MIAO J N, ZHANG S M, et al. Establishment of an orthotopic xenografted animal model of neuroblastoma[J]. Chin J Comp Med, 2021, 31(12):1-6. DOI: 10.3969/j.issn.1671-7856.2021.12.001 .
11	SENEVIRATNE J A, CARTER D R, MITTRA R, et al. Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma[J]. Int J Cancer, 2023, 152(7):1399-1413. DOI: 10.1002/ijc.34349 .
12	MISSIOS P, ROCHA E L DA, PEARSON D S, et al. LIN28B alters ribosomal dynamics to promote metastasis in MYCN-driven malignancy[J]. J Clin Invest, 2021, 131(22):e145142. DOI: 10.1172/JCI145142 .
13	CANDIDO M F, MEDEIROS M, VERONEZ L C, et al. Drugging hijacked kinase pathways in pediatric oncology: opportunities and current scenario[J]. Pharmaceutics, 2023, 15(2):664. DOI: 10.3390/pharmaceutics15020664 .
14	GU Y Y, ZHONG K, PENG L Z, et al. TRAF4 silencing induces cell apoptosis and improves retinoic acid sensitivity in human neuroblastoma[J]. Neurochem Res, 2023, 48(7):2116-2128. DOI: 10.1007/s11064-023-03882-3 .
15	CONDURAT A L, AMINZADEH-GOHARI S, MALNAR M, et al. Verteporfin-induced proteotoxicity impairs cell homeostasis and survival in neuroblastoma subtypes independent of YAP/TAZ expression[J]. Sci Rep, 2023, 13(1):3760. DOI: 10.1038/s41598-023-29796-2 .
16	HE Y, LUO M H, LEI S, et al. Luteoloside induces G0/G1 phase arrest of neuroblastoma cells by targeting p38 MAPK[J]. Molecules, 2023, 28(4):1748. DOI: 10.3390/molecules28041748 .
17	GAO Y, VOLEGOVA M, NASHOLM N, et al. Synergistic anti-tumor effect of combining selective CDK7 and BRD4 inhibition in neuroblastoma[J]. Front Oncol, 2022, 11:773186. DOI: 10.3389/fonc.2021.773186 .
18	MAKVANDI M, SAMANTA M, MARTORANO P, et al. Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma[J]. Commun Biol, 2022, 5(1):1260. DOI: 10.1038/s42003-022-04209-8 .
19	ZHU Q Q, FENG C, LIAO W W, et al. Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model[J]. Cancer Cell Int, 2013, 13(1):65. DOI: 10.1186/1475-2867-13-65 .
20	RYU S, HAYASHI M, AIKAWA H, et al. Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionization mass spectrometry imaging: a pilot study[J]. Br J Pharmacol, 2018, 175(1):29-37. DOI: 10.1111/bph.14067 .
21	NOMURA M, SHIMBO T, MIYAMOTO Y, et al. 13-Cis retinoic acid can enhance the antitumor activity of non-replicating Sendai virus particle against neuroblastoma[J]. Cancer Sci, 2013, 104(2):238-244. DOI: 10.1111/cas.12063 .
22	SEPPORTA M V, PRAZ V, BALMAS BOURLOUD K, et al. TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth[J]. Commun Biol, 2022, 5(1):42. DOI: 10.1038/s42003-021-02958-6 .
23	LAMPIS S, RAIELI S, MONTEMURRO L, et al. The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma[J]. J Exp Clin Cancer Res, 2022, 41(1):160. DOI: 10.1186/s13046-022-02367-5 .
24	XIAO H L, LI Y H, ZHANG Y, et al. Long noncoding RNA LINC01296 regulates the cell proliferation, migration and invasion in neuroblastoma[J]. Metab Brain Dis, 2022, 37(4):1247-1258. DOI: 10.1007/s11011-022-00935-4 .
25	KAMILI A, GIFFORD A J, LI N, et al. Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy[J]. Br J Cancer, 2020, 122(5):680-691. DOI: 10.1038/s41416-019-0682-4 .
26	BYRNE F L, MCCARROLL J A, KAVALLARIS M. Analyses of tumor burden in vivo and metastasis ex vivo using luciferase-expressing cancer cells in an orthotopic mouse model of neuroblastoma[J]. Methods Mol Biol, 2016, 1372:61-77. DOI: 10.1007/978-1-4939-3148-4_5 .
27	GRANT C N, WILLS C A, LIU X M, et al. Thoracic neuroblastoma: a novel surgical model for the study of extra-adrenal neuroblastoma[J]. In Vivo, 2022, 36(1):49-56. DOI: 10.21873/invivo.12675 .
28	WEISS W A, ALDAPE K, MOHAPATRA G, et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice[J]. EMBO J, 1997, 16(11):2985-2995. DOI: 10.1093/emboj/16.11.2985 .
29	MARSHALL G M, CARTER D R, CHEUNG B B, et al. The prenatal origins of cancer[J]. Nat Rev Cancer, 2014, 14(4):277-289. DOI: 10.1038/nrc3679 .
30	Rasmuson A, Segerström L, Nethander M, et al. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma[J]. PLoS One, 2012, 7(12):e51297.
31	ALTHOFF K, BECKERS A, BELL E, et al. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies[J]. Oncogene, 2015, 34(26):3357-3368. DOI: 10.1038/onc.2014.269 .
32	ROSSWOG C, FASSUNKE J, ERNST A, et al. Genomic ALK alterations in primary and relapsed neuroblastoma[J]. Br J Cancer, 2023, 128(8):1559-1571. DOI: 10.1038/s41416-023-02208-y .
33	BRESLER S C, WEISER D A, HUWE P J, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma[J]. Cancer Cell, 2014, 26(5): 682-694. DOI: 10.1016/j.ccell.2014.09.019 .
34	HEUKAMP L C, THOR T, SCHRAMM A, et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice[J]. Sci Transl Med, 2012, 4(141):141ra91. DOI: 10.1126/scitranslmed.3003967 .
35	BERRY T, LUTHER W, BHATNAGAR N, et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma[J]. Cancer Cell, 2012, 22(1):117-130. DOI: 10.1016/j.ccr.2012.06.001 .
36	UEDA T, NAKATA Y, YAMASAKI N, et al. ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN[J]. Oncogene, 2016, 35(34):4447-4458. DOI: 10.1038/onc.2015.519 .
37	LIN Z H, RADAEVA M, CHERKASOV A, et al. Lin28 regulates cancer cell stemness for tumour progression[J]. Cancers, 2022, 14(19):4640. DOI: 10.3390/cancers14194640 .
38	MOLENAAR J J, DOMINGO-FERNÁNDEZ R, EBUS M E, et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression[J]. Nat Genet, 2012, 44(11):1199-1206. DOI: 10.1038/ng.2436 .
39	MASSUDI H, LUO J S, HOLIEN J K, et al. Inhibitors of the oncogenic PA2G4-MYCN protein-protein interface[J]. Cancers, 2023, 15(6):1822. DOI: 10.3390/cancers15061822 .
40	KAMBE K, IGUCHI M, HIGASHI M, et al. Development of minimally invasive cancer immunotherapy using anti-disialoganglioside GD2 antibody-producing mesenchymal stem cells for a neuroblastoma mouse model[J]. Pediatr Surg Int, 2022, 39(1):43. DOI: 10.1007/s00383-022-05310-z .
41	TEITZ T, INOUE M, VALENTINE M B, et al. Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis[J]. Cancer Res, 2013, 73(13):4086-4097. DOI: 10.1158/0008-5472.CAN-12-2681 .
42	YOGEV O, BARKER K, SIKKA A, et al. p53 loss in MYC-driven neuroblastoma leads to metabolic adaptations supporting radioresistance[J]. Cancer Res, 2016, 76(10):3025-3035. DOI: 10.1158/0008-5472.CAN-15-1939 .
43	EIBL R H, SCHNEEMANN M. Medulloblastoma: from TP53 mutations to molecular classification and liquid biopsy[J]. Biology, 2023, 12(2):267. DOI: 10.3390/biology12020267 .
44	MITREVSKA K, MERLOS RODRIGO M A, CERNEI N, et al. Chick chorioallantoic membrane (CAM) assay for the evaluation of the antitumor and antimetastatic activity of platinum-based drugs in association with the impact on the amino acid metabolism[J]. Mater Today Bio, 2023, 19:100570. DOI: 10.1016/j.mtbio.2023.100570 .
45	RIBATTI D, ALESSANDRI G, VACCA A, et al. Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo [J]. Int J Cancer, 1998, 77(3):449-454. DOI: 10.1002/(sici)1097-0215(19980729)77:3449: aid-ijc22>3.0.co;2-1 .
46	MANGIERI D, NICO B, COLUCCIA A M L, al at. An alternative in vivo system for testing angiogenic potential of human neuroblastoma cells[J]. Cancer Lett, 2009, 277(2):199-204. DOI: 10.1016/j.canlet.2008.12.014 .
47	HERRMANN A, RICE M, LÉVY R, et al. Cellular memory of hypoxia elicits neuroblastoma metastasis and enables invasion by non-aggressive neighbouring cells[J]. Oncogenesis, 2015, 4(2): e138. DOI: 10.1038/oncsis.2014.52 .
48	SWADI R, MATHER G, PIZER B L, et al. Optimising the chick chorioallantoic membrane xenograft model of neuroblastoma for drug delivery[J]. BMC Cancer, 2018, 18(1):28. DOI: 10.1186/s12885-017-3978-x .
49	LI S, YEO K S, LEVEE T M, et al. Zebrafish as a neuroblastoma model: progress made, promise for the future[J]. Cells, 2021, 10(3):580. DOI: 10.3390/cells10030580 .
50	STANTON M F. Diethylnitrosamine-induced hepatic degeneration and neoplasia in the aquarium fish, brachydanio rerio[J]. J Natl Cancer Inst, 1965, 34:117-130. DOI: 10.1093/jnci/34.1.117 .
51	LANGENAU D M, TRAVER D, FERRANDO A A, et al. Myc-induced T cell leukemia in transgenic zebrafish[J]. Science, 2003, 299(5608):887-890. DOI: 10.1126/science.1080280 .
52	ETCHIN J, KANKI J P, LOOK A T. Zebrafish as a model for the study of human cancer[J]. Methods Cell Biol, 2011, 105:309-337. DOI: 10.1016/B978-0-12-381320-6.00013-8 .
53	FEITSMA H, CUPPEN E. Zebrafish as a cancer model[J]. Mol Cancer Res, 2008, 6(5):685-694. DOI: 10.1158/1541-7786.MCR-07-2167 .
54	BENJAMIN D C, HYNES R O. Intravital imaging of metastasis in adult Zebrafish[J]. BMC Cancer, 2017, 17(1):660. DOI: 10.1186/s12885-017-3647-0 .
55	TAO T, SONDALLE S B, SHI H, et al. The pre-rRNA processing factor DEF is rate limiting for the pathogenesis of MYCN-driven neuroblastoma[J]. Oncogene, 2017, 36(27):3852-3867. DOI: 10.1038/onc.2016.527 .
56	ZHU S Z, LEE J S, GUO F, et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis[J]. Cancer Cell, 2012, 21(3):362-373. DOI: 10.1016/j.ccr.2012.02.010 .
57	ZHANG X L, DONG Z W, ZHANG C, et al. Critical role for GAB2 in neuroblastoma pathogenesis through the promotion of SHP₂/MYCN cooperation[J]. Cell Rep, 2017, 18(12):2932-2942. DOI: 10.1016/j.celrep.2017.02.065 .
58	COSTA B, ESTRADA M F, MENDES R V, et al. Zebrafish avatars towards personalized medicine-a comparative review between avatar models[J]. Cells, 2020, 9(2):293. DOI: 10.3390/cells9020293 .
59	FIOR R, PÓVOA V, MENDES R V, et al. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts[J]. Proc Natl Acad Sci USA, 2017, 114(39):E8234-E8243. DOI: 10.1073/pnas.1618389114 .
60	ALMSTEDT E, ELGENDY R, HEKMATI N, et al. Integrative discovery of treatments for high-risk neuroblastoma[J]. Nat Commun, 2020, 11(1):71. DOI: 10.1038/s41467-019-13817-8 .
61	VEINOTTE C J, DELLAIRE G, BERMAN J N. Hooking the big one: the potential of zebrafish xenotransplantation to reform cancer drug screening in the genomic era[J]. Dis Model Mech, 2014, 7(7):745-754. DOI: 10.1242/dmm.015784 .
62	HANEY M G, MOORE L H, BLACKBURN J S. Drug screening of primary patient derived tumor xenografts in zebrafish[J]. J Vis Exp, 2020(158):10.3791/60996. DOI: 10.3791/60996 .
63	CABEZAS-SÁINZ P, PENSADO-LÓPEZ A, SÁINZ B Jr, et al. Modeling cancer using zebrafish xenografts: drawbacks for mimicking the human microenvironment[J]. Cells, 2020, 9(9):1978. DOI: 10.3390/cells9091978 .
64	IBARRA B A, JIANG X H, TREFFY R W, et al. Injection of human neuroblastoma cells into neural crest streams in live zebrafish embryos[J]. STAR Protoc, 2022, 3(2):101380. DOI: 10.1016/j.xpro.2022.101380 .
65	DELLOYE-BOURGEOIS C, BERTIN L, THOINET K,et al. Microenvironment-driven shift of cohesion/detachment balance within tumors induces a switch toward metastasis in neuroblastoma[J]. Cancer Cell, 2017, 32(4):427-443.e8. DOI: 10.1016/j.ccell.2017.09.006 .
66	ZHU S Z, ZHANG X L, WEICHERT-LEAHEY N, et al. LMO1 synergizes with MYCN to promote neuroblastoma initiation and metastasis[J]. Cancer Cell, 2017, 32(3):310-323.e5. DOI: 10.1016/j.ccell.2017.08.002 .
67	DONG Z W, YEO K S, LOPEZ G, et al. GAS7 deficiency promotes metastasis in MYCN-Driven neuroblastoma[J]. Cancer Res, 2021, 81(11):2995-3007. DOI: 10.1158/0008-5472.CAN-20-1890 .
68	YANG T Y, LI J H, ZHUO Z J, et al. TTF₁ suppresses neuroblastoma growth and induces neuroblastoma differentiation by targeting TrkA and the miR-204/TrkB axis[J]. iScience, 2022, 25(7):104655. DOI: 10.1016/j.isci. 2022. 104655 .
69	MIAO L, ZHUO Z J, TANG J, et al. FABP4 deactivates NF-κB-IL1α pathway by ubiquitinating ATPB in tumor-associated macrophages and promotes neuroblastoma progression[J]. Clin Transl Med, 2021, 11(4): e395. DOI: 10.1002/ctm2.395 .
70	GARBATI P, BARBIERI R, CALDERONI M, et al. Efficacy of a three drug-based therapy for neuroblastoma in mice[J]. Int J Mol Sci, 2021, 22(13):6753. DOI: 10.3390/ijms22136753 .
71	HARUKI H, PEDERSEN M G, GORSKA K I, et al. Tetrahydrobiopterin biosynthesis as an off-target of sulfa drugs[J]. Science, 2013, 340(6135):987-991. DOI: 10.1126/science.1232972 .
72	SHANG T S, KOTAMRAJU S, ZHAO H T, et al. Sepiapterin attenuates 1-methyl-4-phenylpyridinium-induced apoptosis in neuroblastoma cells transfected with neuronal NOS: role of tetrahydrobiopterin, nitric oxide, and proteasome activation[J]. Free Radic Biol Med, 2005, 39(8):1059-1074. DOI: 10.1016/j.freeradbiomed.2005.05.022 .
73	MOONEY M R, GEERTS D, KORT E J, et al. Anti-tumor effect of sulfasalazine in neuroblastoma[J]. Biochem Pharmacol, 2019, 162:237-249. DOI: 10.1016/j.bcp.2019.01.007 .
74	MAÑAS A, AALTONEN K, ANDERSSON N, et al. Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance[J]. Sci Adv, 2022, 8(43): eabq4617. DOI: 10.1126/sciadv.abq4617 .
75	ZHANG H M, XIA H F, CHEN H, et al. The inhibition of GHR enhanced cytotoxic effects of etoposide on neuroblastoma[J]. Cell Signal, 2021, 86:110081. DOI: 10.1016/j.cellsig. 2021.110081 .
76	NUNES C, DEPESTEL L, MUS L, et al. RRM2 enhances MYCN- driven neuroblastoma formation and acts as a synergistic target with CHK₁ inhibition[J]. Sci Adv, 2022, 8(28): eabn1382. DOI: 10.1126/sciadv.abn1382 .
77	COSTA A, THIRANT C, KRAMDI A, et al. Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma[J]. J Immunother Cancer, 2022, 10(8): e004807. DOI: 10.1136/jitc-2022-004807 .
78	LI N, TORRES M B, SPETZ M R, et al. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice[J]. Cell Rep Med, 2021, 2(6):100297. DOI: 10.1016/j.xcrm.2021.100297 .
79	THERUVATH J, MENARD M, SMITH B A H, et al. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication[J]. Nat Med, 2022, 28(2):333-344. DOI: 10.1038/s41591-021-01625-x .
80	SWADI R R, SAMPAT K, HERRMANN A, et al. CDK inhibitors reduce cell proliferation and reverse hypoxia-induced metastasis of neuroblastoma tumours in a chick embryo model[J]. Sci Rep, 2019, 9(1):9136. DOI: 10.1038/s41598-019-45571-8 .
81	LEIBA J, ÖZBILGIÇ R, HERNÁNDEZ L, et al. Molecular actors of inflammation and their signaling pathways: mechanistic insights from zebrafish[J]. Biology, 2023, 12(2):153. DOI: 10.3390/biology12020153 .

细胞系 Cell line	小鼠品系 Mouse stain	MYCN基因状态 MYCN status	ALK基因突变 ALK mutation	P53基因突变 P53 mutation	参考文献 Reference
KELLY	BALB/c-nude小鼠	扩增	野生型	野生型	[11]
CHP-212	NSG小鼠	扩增	野生型	野生型	[12]
SKNAS	BALB/c-nude小鼠	非扩增	野生型	H168R	[13]
SH-SY-5Y	Foxn1nu/Nju小鼠、ICR小鼠、BALB/c-nude小鼠	非扩增	F1174L	野生型	[14-16]
IMR-32	NSG小鼠	扩增	野生型	野生型	[17]
IMR-05	SHC小鼠	扩增	野生型	野生型	[18]
LA-N-5	BALB/c-nude小鼠	扩增	R1275Q	野生型	[19]
NB-1	BALB/c-nude小鼠	扩增	野生型扩增	野生型	[20-21]
SK-N-BE(2)	SCID-Beige小鼠	扩增	野生型	C135F	[10]
SK-N-BE(2)-C	BALB/c- nude小鼠、Foxn1nu/Nju小鼠	扩增	野生型	C135F	[11, 22]
CHP-134	NOD-SCID小鼠	扩增	野生型	野生型	[23]
SK-N-DZ	BALB/c-nude小鼠	扩增	野生型	R110L	[24]

细胞系 Cell line	小鼠品系 Mouse stain	MYCN基因状态 MYCN status	ALK基因突变 ALK mutation	P53基因突变 P53 mutation	参考文献 Reference
KELLY	BALB/c-nude小鼠	扩增	野生型	野生型	[11]
CHP-212	NSG小鼠	扩增	野生型	野生型	[12]
SKNAS	BALB/c-nude小鼠	非扩增	野生型	H168R	[13]
SH-SY-5Y	Foxn1nu/Nju小鼠、ICR小鼠、BALB/c-nude小鼠	非扩增	F1174L	野生型	[14-16]
IMR-32	NSG小鼠	扩增	野生型	野生型	[17]
IMR-05	SHC小鼠	扩增	野生型	野生型	[18]
LA-N-5	BALB/c-nude小鼠	扩增	R1275Q	野生型	[19]
NB-1	BALB/c-nude小鼠	扩增	野生型扩增	野生型	[20-21]
SK-N-BE(2)	SCID-Beige小鼠	扩增	野生型	C135F	[10]
SK-N-BE(2)-C	BALB/c- nude小鼠、Foxn1nu/Nju小鼠	扩增	野生型	C135F	[11, 22]
CHP-134	NOD-SCID小鼠	扩增	野生型	野生型	[23]
SK-N-DZ	BALB/c-nude小鼠	扩增	野生型	R110L	[24]

小鼠模型 Mouse model	优势 Advantage	局限性 Limitation	参考文献 Reference
Th-MYCN	代表高危NB型，成瘤率高	成瘤时间长，转移少	[39-40]
LSL-MYCN;dβh-iCre	比Th-MYCN更明确的转基因插入，发病率更高	转移率低	[31]
Th-MYCN/CASP8(KO)	存在转移，成瘤率高	引起原发肿瘤细胞外基质结构的改变	[41]
Th-MYCN/Trp53(KI)	诱导性P53丢失	P53突变多发于复发肿瘤中，小鼠的存活率低	[42]
ALK(F1174)	符合NB表型	临床常见率低	[33]
Th-MYCN/ALK(F1174)	成瘤率高，肿瘤生长快	相关性低	[35]
SV40 Tag	与NB表型一致，肿瘤发病率高，存在转移	所有小鼠在28周龄前死亡	[43]

小鼠模型 Mouse model	优势 Advantage	局限性 Limitation	参考文献 Reference
Th-MYCN	代表高危NB型，成瘤率高	成瘤时间长，转移少	[39-40]
LSL-MYCN;dβh-iCre	比Th-MYCN更明确的转基因插入，发病率更高	转移率低	[31]
Th-MYCN/CASP8(KO)	存在转移，成瘤率高	引起原发肿瘤细胞外基质结构的改变	[41]
Th-MYCN/Trp53(KI)	诱导性P53丢失	P53突变多发于复发肿瘤中，小鼠的存活率低	[42]
ALK(F1174)	符合NB表型	临床常见率低	[33]
Th-MYCN/ALK(F1174)	成瘤率高，肿瘤生长快	相关性低	[35]
SV40 Tag	与NB表型一致，肿瘤发病率高，存在转移	所有小鼠在28周龄前死亡	[43]

[1]	王娟, 徐佳慧, 田韵远, 张萌萌, 李敏, 王四旺, 李瑶. 两种雌性小鼠溃疡性结肠炎模型的比较与行为学观察[J]. 实验动物与比较医学, 2026, 46(3): 332-343.
[2]	卜纪雯, 华叶, 金仕容, 任宁欣, 李福宁, 杜久林. 斑马鱼品系及斑马鱼鱼房的自动化管理[J]. 实验动物与比较医学, 2026, 46(3): 416-425.
[3]	潘林琴, 邓向亮, 罗云霞. 缺血性脑卒中动物模型的中西医整合转化研究进展[J]. 实验动物与比较医学, 2026, 46(3): 344-356.
[4]	李龙雪, 万崇凡, 张琦, 雷茹婷, 王潇玥, 程乐妍, 赖琦, 刘荣华, 刘漩, 徐铁龙. 基于miRNA测序分析清肺排毒汤防治小鼠急性肺损伤的分子机制研究[J]. 实验动物与比较医学, 2026, 46(3): 311-320.
[5]	艾秀峰, 张利棕, 方明笋, 吕东颖, 陈楚, 蔡兆伟, 王德军. 16S rRNA测序分析饮用含氯水对大鼠和小鼠肠道菌群的影响差异[J]. 实验动物与比较医学, 2026, 46(3): 437-445.
[6]	周忆旻, 张昕宇, 杨佳诺, 刘梦佳, 司灿灿, 叶海绿, 孙文超, 兰添. MHV、MPV和Reo-3三重TaqMan定量PCR检测方法的建立[J]. 实验动物与比较医学, 2026, 46(3): 408-415.
[7]	中国研究型医院学会医学动物实验专家委员会, 中国医药生物技术协会再生医学分会, 韩发彬, 陈琳, 陈志国, 卢明, 李英俊. 帕金森病药物和干细胞治疗临床前动物实验模型选择指南（2026年版）[J]. 实验动物与比较医学, 2026, 46(2): 153-177.
[8]	李慧. 生物语言学动物模型研究进展[J]. 实验动物与比较医学, 2026, 46(2): 297-305.
[9]	荣文双, 牛源菲, 刘美婷, 杨梦园, 崔爽, 马丽娜, 富尧, 王连嵋, 曹俊岭. 抗原类型对诱导型干燥综合征小鼠建模的影响[J]. 实验动物与比较医学, 2026, 46(2): 178-190.
[10]	刘赛, 付彬, 李思迪, 陈志达, 张悦, 郭中坤, 王永安, 王可洲. Adra2a通过MAPK信号通路介导LPS诱导的Lbp^-/-小鼠肝细胞炎性反应[J]. 实验动物与比较医学, 2026, 46(2): 212-221.
[11]	赵赫, 张涛, 李丽, 肖宇宙, 安学芳, 张帆. 猪抑制素多克隆抗体对C57BL/6J小鼠超数排卵的增效作用[J]. 实验动物与比较医学, 2026, 46(2): 271-278.
[12]	崔畅婉, 路一平, 于淼, 王爽, 吴思, 孙峥嵘. 溶质载体家族7成员5抑制剂JPH203对单侧输尿管梗阻诱导小鼠肾纤维化的抑制作用[J]. 实验动物与比较医学, 2026, 46(2): 205-211.
[13]	吴宪文, 刘丽丽, 陈烨, 徐国恒. 繁育体系中育成期小鼠换笼周期及刨花垫料使用量的优化研究[J]. 实验动物与比较医学, 2026, 46(2): 251-260.
[14]	陈子宜, 孙红燕, 康品方, 武文娟. 肺动脉高压动物模型构建方法及新型技术研究进展[J]. 实验动物与比较医学, 2026, 46(1): 81-93.
[15]	徐波, 陈泰任, 方乾, 吴际. 脊髓压迫和半横断损伤小鼠模型的时空基因表达谱及修复机制研究[J]. 实验动物与比较医学, 2026, 46(1): 32-45.

神经母细胞瘤动物模型研究进展与应用

Advances and Applications in Animal Models of Neuroblastoma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 81

相关文章 15

编辑推荐

Metrics

本文评价